page 1 page 2 page 3 page 4 page 5 page 6 page 7 page 8 page 9 page 10 page 11 page 12 page 13 page 14 page 15 page 16 page 17 page 18 page 19 page 20 page 21 page 22 page 23 page 24 page 25 page 26 page 27 page 28 page 29 page 30 page 31 page 32 page 33 page 34 page 35 page 36 page 37 page 38 page 39 page 40 page 41 page 42 page 43 page 44 page 45 page 46 page 47 page 48 page 49 page 50 page 51 page 52 page 53 page 54 page 55 page 56 page 57 page 58 page 59 page 60 page 61 page 62 page 63 page 64 page 65 page 66 page 67 page 68 page 69 page 70 page 71 page 72 page 73 page 74 page 75 page 76 page 77 page 78 page 79 page 80 page 81 page 82 page 83 page 84 page 85 page 86 page 87 page 88 page 89 page 90 page 91 page 92 page 93 page 94 page 95 page 96 page 97 page 98 page 99 page 100 page 101 page 102 page 103 page 104 page 105 page 106 page 107 page 108 page 109 page 110 page 111 page 112 page 113 page 114 page 115 page 116 page 117 page 118 page 119 page 120 page 121 page 122 page 123 page 124 page 125 page 126 page 127 page 128 page 129 page 130 page 131 page 132 page 133 page 134 page 135 page 136 page 137 page 138 page 139 page 140 page 141 page 142 page 143 page 144 page 145 page 146 page 147 page 148 page 149 page 150 page 151 page 152 page 153 page 154 page 155 page 156 page 157 page 158 page 159 page 160 page 161 page 162 page 163 page 164 page 165 page 166 page 167 page 168 page 169 page 170 page 171 page 172 page 173 page 174 page 175 page 176 page 177 page 178 page 179 page 180 page 181 page 182 page 183 page 184 page 185 page 186
|
78INNOVATION UK MATCH and the NIC together with the participation of the innovator or clinical champion. With an increasing need to identify additional spending with metrics of patient benefit, the wider application of basic cost- effectiveness analysis has become necessary outside the usual expert base of health technology assess-ment specialists. In the context of the findings of the UK Health Industries Task Force, that a better assessment of value is required to bring new health technologies into the National Health Service, the tool described is seen to be facilitating a common understanding of value between healthcare decision- makers and medical device develop-ers or clinician " champions" who are amongst the first adopters of newly marketed devices. Further exemplar work is needed to examine the gener-alisability of the tool in terms of number and depth of decision- tree branches, balanced with a requirement to keep the model simple for non- expert use, and in the knowledge that data for a more complex model will be limited at the early stage of an innovation's develop-ment or deployment. As stated repeatedly, the tool is not intended to replace the need for a full NICE appraisal using a more complete data set, accepting that limited data will be the norm for early stage decisions. However more work needs to be done to examine the sensitivity to estimated data ranges and especially to research the effect on decisions from the making of optimistic or pes-simistic estimates. Conducting these exemplar studies with the tool on real users during its development prompted discussion about the " percentage cost modifier parameter". The rationale for inclusion of the feature was based on an example of a diagnostic device designed to assess burns by means of blood- flow measurement, where the treatment is a skin graft. If the innovation resulted in better assessment of the area in need of grafting, it was argued that this could be modelled as an efficiency saving in the treatment and therefore cost of treatment could be reduced accord-ingly. However, for general use it is perhaps too tempting to use it as a " fudge factor" to reduce the relative cost of the innovation. We have now decided to remove the feature and the user should enter cost savings to treat-ments directly. A major lesson learnt from the exemplar work is that lack of hard data is not a barrier to mutual understanding of value at the early stage of development or deployment of a medical technology innovation. We also found that data may exist but not be readily available, which sug-gests that wider deployment of the tool would ideally be supported by an accessible repository of data for the pur-poses of health economics evaluation. Most importantly the tool was developed in close partnership with its users. The close academic- industry- healthcare professional linkage facilitated by MATCH supports and actively pro-motes this kind of co- operative design approach. All of the focused evaluation meetings were carried out over a half- day period. However, some preparation is needed by all parties. Since conducting these exemplars, and after further consultations with partners in the medi-cal devices industry, we have identified that an introduc-tion to health economics, data sources and some hands-on training with the tool prior to the evaluation meeting would be beneficial. MATCH therefore decided to launch a series of tool workshops through the UK- wide Medilink network which brings together medical manufacturing and distribution companies, hospitals and universities to stimulate innovation on a regional basis. This is taking place alongside a new phase of exemplar studies with both NIC and PASA. This article is an abridged version of a paper first pub-lished in Journal of Management & Marketing in Healthcare Volume 2 Issue 3 ( September 2009). For further details visit http:// www. henrystewart. com/ jmmh For more information about this tool and other tools and methods developed by the Innovative Manufactur-ing Research Centre MATCH for use by Medical Device manufacturers, or for information about the benefits of becoming a MATCH Partner, please visit www. match. ac. uk or contact elizabeth. deadman@ brunel. ac. uk 1 NHS Institute for Innovation and Improvement, " Better Care, Better Value Indicators", http:// www. productivity. nhs. uk ( accessed Sep-tember 2008). 2 Healthcare Industries Task Force ( HITF) " Better health through partnership: A programme for action", 17 November 2004, http:// www. advisorybodies. doh. gov. uk/ hitf/ ( accessed August 2007). 3 Strategic Implementation Group ( SIG), Healthcare Industries Taskforce, Innovation for health: making a difference, 6 March 2007, http:// www. advisorybodies. doh. gov. uk/ hitf/ ( accessed August 2007). 4 NHS National Innovation Centre, Scorecard, http:// www. nic. nhs. uk/ Scorecard/ Pages/ Scorecard. aspx ( accessed October 2007) 5 Craven M., Crowe J., Botterill N., Morgan S. and Williams H., MATCH ( 2004): A multidisciplinary approach to the advancement of Health Technology Assessment, Proceedings of the Institute of Physics and Engineering in Medicine ( IPEM) 11th Annual Scientific Meeting, York, 6- 8 September 2004, p; 41, ISBN 1- 9036- 1323- X. First appeared in the Journal of Management & Marketing in Healthcare. VOL. 2 NO. 3. PP 1- 15. MONTH 2009 Healthcare match INNOVATION UK79 Healthcare integrated technologies ltd Integrated Technologies Ltd - Bringing Instruments to Life At Integrated Technologies Ltd ( ITL) " Bringing Instruments to Life" isn't just a strap line; it is a way of thinking. ITL has over 35 years of experience in successful design, development, prototype and manufacture of instru-ments and devices for the medical, diagnostic, analytical and laboratory markets. We offer all the services of a design house, a regulatory consultancy and a manufac-turing facility under one roof and that makes a differ-ence to the way we think and the way we design. Our new product development cycle has been developed to consider the entirety of your product's life, not just one stage of the process, to turn a requirement into a final product. We find appropriate state- of- the- art practi-cal engineering solutions that can be progressed to our full- scale manufacturing facility. From the start of the design we are considering the manufacture of your prod-uct and have an insight into its future, and that means that the commercial reality is the focus throughout the development process. Behind every truly successful stylish design there is bril-liant engineering. Your product has its own set of mar-keting requirements such as beautiful styling, a clear easy- to- use interface and labelling and clever software. It may also have a set of functional requirements such as short time to result, unique disposable handling or a particular detection mechanism. Translating your basic requirements into a robust, cost- effective, easy- to- man-ufacture working solution is a skill of its own. At ITL we understand just how much elegance, sophistication and ergonomics are required to deliver an instrument that fits in today's marketplace. Working with you to make it hap-pen involves innovative thinking and a level of creativity along with trusted engineering. In fact graceful mecha-nisms, high- technology solutions and truly clever designs are what we are all about. Furthermore we understand that visual aesthetics of a product are very important and therefore our industrial design expertise ensures that our elegant engineering solutions are packaged into stylish overall designs. Full- scale manufacture is available from ITL both in the UK and in the Far East, not just for ITL designed products but also for products that are prototyped and ready for manufacture or already in manufacture. Highly skilled assembly, test and quality assurance processes are con-ducted within a cellular manufacturing environment alongside supply chain management and Kanban stock control systems. ITL has in- house PCB manufacture and in- line process control and inspection mechanisms and can undertake all aspects of product packaging, labelling and secure cargo shipping. Having dedicated in- house Production Engineering resource and access to Develop-ment Engineers enables smooth design- change control, obsolescence control and value engineering. Design and manufacture within a quality controlled envi-ronment is vital to the commercial success of a prod-uct in today's market. ITL is certified to ISO9001: 2000, BSEN 13485: 2003, FDA GMP 21 CFR part 820 making it the perfect place for design and manufacture of worldwide products. ITL offers you the opportunity to complete product development and manufacture within one organisation without the need to transfer knowledge between a design house, a prototyping company and a manufacturing facility. One company, one specification, one vision, one team, one system, one solution. How simple is that? For more information, contact: Integrated Technologies Ltd Viking House Ellingham Way Ashford Kent TN23 6NF Lucy Malby Website: www. itl. co. uk E- mail: sales@ itl. co. uk Tel: + 44 ( 0) 1233 638383 Design Prototype Manufacture |